A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment

计划入组 100 人 · 首次发布于 2026 年 8 月 25 日

Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)

计划入组 500 人 · 首次发布于 2023 年 10 月 30 日

Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)

计划入组 400 人 · 首次发布于 2021 年 7 月 2 日

iPSC-derived allogenic cell therapy (immune thrombocytopenia)

apoptosis inhibitors (thrombocytopenia)

mRNA vaccine (thrombocytopenia Syndrome)

PRIMARY PHARMACEUTICALS, INC.

United States

PRIMARY HEALTH CARE CORPORATION

Qatar

AC Immune

Switzerland

InnoCare's Orelabrutinib Shows Promise in Treating Primary Immune Thrombocytopenia

FDA Grants Orphan Drug Designation to Novartis' Ianalumab for Primary Immune Thrombocytopenia

INNOCARE's BTK Inhibitor Orelabrutinib Receives New Drug Application Acceptance in China for Primary Immune Thrombocytopenia Treatment